首页> 外文OA文献 >Hospitalization for Invasive Pneumococcal Diseases in Young Children before Use of 13-Valent Pneumococcal Conjugate Vaccine, Suzhou, China
【2h】

Hospitalization for Invasive Pneumococcal Diseases in Young Children before Use of 13-Valent Pneumococcal Conjugate Vaccine, Suzhou, China

机译:在使用13价肺炎球菌缀合物疫苗前,幼儿入院治疗幼儿血液球菌疾病,苏州

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A 13-valent pneumococcal conjugate vaccine against invasive pneumococcal disease (IPD) was introduced in China in April 2017. We describe 105 children <5 years of age who were hospitalized for IPD at Soochow University Affiliated Children’s Hospital in Suzhou, China, during January 2010–December 2017. We calculated the incidence of hospitalization for IPD as 14.55/100,000 children in Suzhou. We identified 8 different capsular serotypes: 6B (28.4% of cases), 14 (18.9% of cases), 19A (18.9% of cases), 19F (12.2% of cases), 23F (10.8% of cases), 20 (4.1% of cases), 9V (4.1% of cases), and 15B/C (2.7% of cases). These results provide baseline data of IPD before the introduction of this vaccine in China, enabling researchers to better understand its effects on IPD incidence.
机译:2010年4月,中国在中国引入了针对侵袭性肺炎球菌疾病(IPD)的13价肺炎球菌缀合物疫苗(IPD)。我们在2010年1月苏州苏州苏州苏州附属儿童医院住院105名儿童<5岁儿童 - 2017年。我们计算了苏州IPD为14.55 / 100,000名儿童住院治疗的发病率。我们确定了8种不同的血型血清型:6B(28.4%的病例),14例(案件的18.9%),19a(18.9%的病例),19°F(12.2%的病例),23°F(10.8%的病例),20(4.1病例的%),9V(4.1%的病例)和15b / c(2.7%的病例)。这些结果在中国引入这种疫苗之前提供了IPD的基线数据,使研究人员能够更好地了解其对IPD发病率的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号